TNFi not linked to increased cancer recurrence in RA patients

TNFi not linked to increased cancer recurrence in RA patients

(HealthDay)—For patients with rheumatoid arthritis (RA), treatment with tumor necrosis factor inhibitors (TNFi) is not associated with increased risk for cancer recurrence, according to a study published online Aug. 14 in the Annals of Internal Medicine.

Pauline Raaschou, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues conducted a population-based cohort study based on linkage of nationwide registers to examine whether TNFi treatment in RA is associated with increased risk for .

The researchers found that 42 of the 467 patients who started TNFi treatment at a mean of 7.9 years after diagnosis had cancer recurrence (9.0 percent); 155 of 2,164 matched patients with the same cancer history had recurrences (7.2 percent) (hazard ratio, 1.06; 95 percent confidence interval, 0.73 to 1.54). In analyses of subsets of patients matched on cancer stage or with similar time from index cancer diagnosis to the start of TNFi treatment and in unmatched analyses, the hazard ratios were close to 1.

"The findings suggest that TNFi is not associated with increased risk for cancer in patients with RA, although meaningful risk increases could not be ruled out completely," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.


Explore further

ACR: TNF inhibitors linked to reduced risk of ACS in RA

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: Annals of Internal Medicine

Copyright © 2018 HealthDay. All rights reserved.

Citation: TNFi not linked to increased cancer recurrence in RA patients (2018, August 24) retrieved 24 October 2020 from https://medicalxpress.com/news/2018-08-tnfi-linked-cancer-recurrence-ra.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments